GlassScriptPhysician profile
William Doty Farmer
NPI 1902840861
$4,030.26
in general payments reported to CMS, 2019-2025
31 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $62.95 · 2021: $289 · 2022: $521 · 2023: $865 · 2024: $722 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,689 · Entertainment: $30.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,688.72 |
| Entertainment | $30.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $594.84 | 2019-2025 | Xifaxan |
| Abbvie INC. | $506.85 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $373.30 | 2021-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $353.88 | 2019-2025 | Entyvio, Eohilia |
| Amgen INC. | $249.91 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $248.10 | 2022-2025 | Rocklatan, Clareon |
| Rxsight INC | $231.37 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Novartis Pharmaceuticals Corporation | $206.04 | 2020-2023 | |
| Bausch & Lomb Americas INC. | $172.05 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Oyster Point Pharma, INC. | $124.29 | 2022-2024 | Tyrvaya |
| Horizon Therapeutics Plc | $93.65 | 2022-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $90.00 | 2019 | |
| Janssen Biotech, INC. | $89.25 | 2023 | Stelara, Simponi, Simponi Aria |
| Allergan, INC. | $84.38 | 2019-2021 | |
| Thea Pharma INC. | $75.37 | 2023-2025 | Iyuzeh |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $63.95 | 2019-2023 | Cequa |
| Glaukos Corporation | $58.46 | 2024-2025 | Idosetr, Idose |
| Sight Sciences, INC. | $49.04 | 2022-2023 | Omni Surgical System |
| Biotissue Holdings INC. | $48.74 | 2022 | |
| Ani Pharmaceuticals, INC. | $45.50 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $38.97 | 2023-2025 | Vabysmo |
| Dompe US, INC. | $38.36 | 2021-2022 | |
| Nova Eye, INC. | $30.37 | 2025 | |
| Apellis Pharmaceuticals, INC. | $26.24 | 2023 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $25.58 | 2024 | Xdemvy |
| Ocular Therapeutix, INC. | $23.72 | 2023 | Dextenza |
| Harrow Eye, LLC | $20.57 | 2025 | Triesence |
| Rayner Intraocular Lenses Limited | $18.89 | 2024 | Omidria |
| Aerie Pharmaceuticals, INC. | $18.62 | 2019 | |
| Halozyme INC | $18.07 | 2023 | |
| Evoke Pharma, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.